This is a preview of subscription content, log in via an institution to check access.
References
Boehringer Mannheim. Ibandronate in hypercalcemia of malignancy. Boehringer Mannheim 1996 Jun; 1–59
Ravn P, Clemmesen B, Riis BJ, et al. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis. A 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 1996 Nov; 19: 527–33
Monierfaugere MC, Friedler RM, Bauss F, et al. A new bisphosphonate, BM-21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res 1993 Nov; 8: 1345–55
Fleisch H. The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by Ca-45 kinetics in the intact rat. Osteoporos Int 1996; 6 (2): 166–70
Thiéaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997 Oct; 103: 298–307
Rights and permissions
About this article
Cite this article
Ibandronic Acid. Drugs R&D 1, 215–217 (1999). https://doi.org/10.2165/00126839-199901030-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199901030-00005